Flash Therapeutics

Based on its proprietary LentiFlash® technology and its manufacturing subsidiary Vectalys, the company has the potential to drive and advance the development of therapeutic methods mediated by RNA and DNA delivery for the treatment of a variety of diseases, including cancer, infectious diseases, and genetic disorders.